ADMA Biologics Inc reports results for the quarter ended June 30 - Earnings Summary

• ADMA Biologics Inc ADMA reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 13 cents. The mean expectation of three analysts for the quarter was for earnings of 14 cents per share.

• Revenue rose 13.8% to $121.98 million from a year ago; analysts expected $122.67 million.

• ADMA Biologics Inc's reported EPS for the quarter was 14 cents​.

• The company reported quarterly net income of $34.22 million.

• ADMA Biologics Inc shares had risen by 4.1% this quarter and gained 10.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 16% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for ADMA Biologics Inc is $31.00, about 38.8% above its last closing price of $18.96

This summary was machine generated from LSEG data August 6 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)